
|Articles|September 29, 2021
LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials
Advertisement
LEO Pharma and Veeva Systems have announced a strategic technology partnership to enable scalable digital trials that are patient-centric and paperless. LEO Pharma will utilize the integrated suite of Veeva clinical products, including eTMF, CTMS, CDMS, Site Connect, eConsent, ePRO, Virtual Visits, and eSource.
By adopting technology and business processes, LEO Pharma hopes to achieve the following:
- Significantly improved patient experience
- Increased patient diversity through decentralized trials
- Higher accuracy in clinical data
- 25% reduction in clinical trial cost
- 25% reduction in clinical trial time
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Patient Centricity: What Rare Disease Research Gets Right
2
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
3
ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD
4
The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness
5




